Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (211-220 of 294) with videos related to

Pageof 30
Sort By:
Nature Reviews. Urology|May 22, 2023
Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
European Urology|August 18, 2023
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605Peter C Black, Catherine M Tangen, Parminder Singh, et al.
Journal of the National Cancer Institute|January 15, 2009
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancerVitaly Margulis, Yair Lotan, Pierre I Karakiewicz, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not MatterAshish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Clinical Chemistry|March 9, 2010
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancersCatharine M Sturgeon, Michael J Duffy, Barry R Hofmann, et al.
European Urology|May 17, 2023
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk FactorsIbrahim Jubber, Sean Ong, Laura Bukavina, et al.
Cancer|March 5, 2013
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working GroupMatthew D Galsky, Ryan Hendricks, Robert Svatek, et al.
BJU International|July 17, 2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaAbhishek Tripathi, Catherine M Tangen, Melissa Plets, et al.
The Journal of Urology|January 24, 2016
Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of SurvivalFriedrich-Carl von Rundstedt, Kimal Rajapakshe, Jing Ma, et al.
Clinical Genitourinary Cancer|December 12, 2012
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancerMatthew D Galsky, Noah M Hahn, Thomas Powles, et al.
Pageof 30

Showing results (211-220 of 294) with videos related to

Sort By:
Pageof 30
Nature Reviews. Urology|May 22, 2023
Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic diseaseKyle M Rose, Heather L Huelster, Joshua J Meeks, et al.
European Urology|August 18, 2023
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605Peter C Black, Catherine M Tangen, Parminder Singh, et al.
Journal of the National Cancer Institute|January 15, 2009
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancerVitaly Margulis, Yair Lotan, Pierre I Karakiewicz, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not MatterAshish M Kamat, Niyati Lobo, Seth P Lerner, et al.
Clinical Chemistry|March 9, 2010
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancersCatharine M Sturgeon, Michael J Duffy, Barry R Hofmann, et al.
European Urology|May 17, 2023
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk FactorsIbrahim Jubber, Sean Ong, Laura Bukavina, et al.
Cancer|March 5, 2013
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working GroupMatthew D Galsky, Ryan Hendricks, Robert Svatek, et al.
BJU International|July 17, 2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaAbhishek Tripathi, Catherine M Tangen, Melissa Plets, et al.
The Journal of Urology|January 24, 2016
Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of SurvivalFriedrich-Carl von Rundstedt, Kimal Rajapakshe, Jing Ma, et al.
Clinical Genitourinary Cancer|December 12, 2012
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancerMatthew D Galsky, Noah M Hahn, Thomas Powles, et al.
Pageof 30